Good afternoon :)
$
₹
Atossa Genetics Inc

Atossa Genetics Inc

ATOS

NASDAQ
Asset Logo

Atossa Genetics Inc

ATOS

NASDAQ
$2.119.22% (-0.21)
$
₹
$2.119.22% (-0.21)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $23.0M the stock is ranked 5408

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.81
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.45
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+715.45%

Earnings Growth

+15.04%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
40.95
40.95
1Y Return
13.03%
13.03%
Buy Reco %
82.14
82.14
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
37.74
37.74
1Y Return
7.61%
7.61%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
52.82
52.82
1Y Return
10.52%
10.52%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.69
23.69
1Y Return
16.08%
16.08%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
32.67
32.67
1Y Return
6.33%
6.33%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 715.45% growth, versus a trailing 3-year CAGR of 50.76%.

2026
Current$2.33Baseline
Analyst Target - 1 year
Target$19+715.45%

All values in $

202220232024202520262027$5.58$10.69$15.79Target+715.45%
2026
Current$2.33Baseline
Analyst Target - 1 year
Target$19+715.45%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-4.19Baseline
Forecast for Dec 2026
High$-3.56+15.04%
Average$-3.56+15.04%
Low$-3.56+15.04%

All values in $

202120222023202420252026-2.14-3.15-2.09-2.45-4.19Low+15.04%Average+15.04%High+15.04%
2025
Current$-4.19Baseline
Forecast for Dec 2026
High$-3.56+15.04%
Average$-3.56+15.04%
Low$-3.56+15.04%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-8.6
-10.9
-9.5
-8.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.01000000000
Net Income-5.87-6.04-7.23-6.34-6.71-8.42-8.69-10.93-9.58-8.49
Net Profit Margin-32655.55%---------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Atossa Genetics Inc -0.810
Abbott Laboratories40.953.591.51
Danaher Corporation37.743.041.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ATOS with any stock or ETF
Compare ATOS with any stock or ETF
Comparing from
ATOS
ABT
DHR
Loading...

Frequently asked questions

  1. Atossa Genetics Inc (ATOS) share price today is $2.11 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $2.32 and a day low of $2.08.

  2. Atossa Genetics Inc stock trades on NASDAQ under the ticker symbol ATOS.

  3. Atossa Genetics Inc's market capitalization is $22.95M as of November 5, 2026 at 2:29 AM IST.

  4. Atossa Genetics Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Atossa Genetics Inc's price-to-book (P/B) ratio is 0.81 as of November 4, 2026.

  6. Yes, You can buy Atossa Genetics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Atossa Genetics Inc shares in three steps: 1. Search Atossa Genetics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Atossa Genetics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Atossa Genetics Inc (ATOS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.7281 shares at the current price of $2.11.

Loading...